Entry Information
Hui Wan
Dr
Female

14/12/1992
China
Passport
EK789
Chinese
Email hidden; Javascript is required.
+46720017019
Solnavägen 9, floor 9D
Stockholm
Sweden
Life Science and Medicine
N/A
I am eager to apply for the upcoming Forum in Hong Kong. As a young scientist passionate about innovative research, I see this forum as an excellent opportunity for insights and networking that will enrich my academic and professional journey. My current research focuses on normal B-cell immunity against infections and the tumorigenesis and treatment of B-cell lymphoma, where I have developed strong bioinformatics skills. Participating in this forum will enable me to engage with leading experts and fellow scientists, fostering collaborations that can advance my work and contribute to the scientific community. Additionally, as I have never visited Hong Kong, I am excited to visit the city, explore its scientific landscape, and seek research opportunities there using this opportunity.
Postdoc
Cancer genetics; Immunology; Bioinformatics
Karolinska Institutet
Stockholm
First Academic or Research Referee *
Prof. Qiang Pan-Hammarström
Karolinska Institutet
Professor
Email hidden; Javascript is required.
Second Academic or Research Referee
My research focuses on developing personalized therapy for patients with B cell lymphomas by utilizing genetic and prognostic models. I am investigating tumor evolution and the mutational signature of various B-cell malignancies. My work integrates cutting-edge bioinformatics techniques, including single-cell RNA sequencing and whole-genome sequencing, to uncover the genetic underpinnings of these cancers.
Additionally, I have contributed to several notable projects, such as examining the persistence of immune responses in convalescent COVID-19 patients and investigating immunity against the SARS-CoV-2 Omicron variant through diverse vaccination strategies.
Through my research, I aim to enhance our understanding of B cell immunity and how it becomes B-cell lymphomas and improve therapeutic outcomes for lymphoma patients, paving the way for tailored treatments that cater to individual patient profiles.
Poster Presentation Session
N/A
Peers
